Tehran University of Medical Sciences

Science Communicator Platform

Stay connected! Follow us on X network (Twitter):
Share this content! On (X network) By
Efficacy and Safety of Celecoxib Monotherapy for Mild to Moderate Depression in Patients With Colorectal Cancer: A Randomized Double-Blind, Placebo Controlled Trial Publisher Pubmed



Alamdarsaravi M1 ; Ghajar A2 ; Noorbala AA1 ; Arbabi M1 ; Emami A3 ; Shahei F3 ; Mirzania M3 ; Jafarinia M1 ; Afarideh M2 ; Akhondzadeh S2
Authors
Show Affiliations
Authors Affiliations
  1. 1. Psychosomatic Research Center, Imam Hospital, Tehran University of Medical Sciences, Tehran, Iran
  2. 2. Psychiatric Research Center, Roozbeh Hospital, Tehran University of Medical Sciences, South Kargar Street, Tehran, 13337, Iran
  3. 3. Hematology and Medical Oncology Ward, Imam Hospital, Tehran University of Medical Sciences, Tehran, Iran

Source: Psychiatry Research Published:2017


Abstract

Cancer-related inflammation is an essential process in malignancies. Celecoxib, a nonsteroidal anti-inflammatory drug that acts via the selective inhibition of cyclooxygenase (COX)-2, has shown favorable effects in several psychiatric disorders. The present study aimed to assess the safety and efficacy of celecoxib single therapy on depressive symptoms of patients with colorectal cancer who underwent chemotherapy. The study was conducted as a 6-week, parallel-group, randomized, double-blind, placebo-controlled trial. Forty participants randomly received either 400 mg/day celecoxib or placebo. Treatment effect was assessed using the Hamilton Depression Rating Scale (HDRS) and Visual Analogue Scale (VAS) score at baseline and at week 2, 4 and 6 of the trial. Over 6 weeks, patients who received celecoxib showed significant improvement in scores of the Hamilton Depression rating Scale (P=0.003). When comparing the Mean Difference (95% CI) between the two groups of therapy, the celecoxib group demonstrated greater reduction in HDRS score during the study period at weeks 4 (1.95, 95% CI 0.27–3.63, P value =0.024) and 6 (2.60, 95% CI 0.96–4.23, P=0.003). This study indicates celecoxib as a potential monotherapy treatment strategy for mild to moderate depression in patients with colorectal cancer who underwent chemotherapy. © 2017 Elsevier Ireland Ltd
Related Docs
View other Related Docs
1. Celecoxib Versus Diclofenac in Mild to Moderate Depression Management Among Breast Cancer Patients: A Double-Blind, Placebo-Controlled, Randomized Trial, Annals of Pharmacotherapy (2015)
2. Celecoxib for the Treatment of Mild-To-Moderate Depression Due to Acute Brucellosis: A Double-Blind, Placebo-Controlled, Randomized Trial, Journal of Clinical Pharmacy and Therapeutics (2015)
3. A Randomized, Double-Blind Placebo-Controlled Trial on Effectiveness and Safety of Celecoxib Adjunctive Therapy in Adolescents With Acute Bipolar Mania, Journal of Child and Adolescent Psychopharmacology (2017)
4. Therapeutic Effects of Minocycline on Mild-To-Moderate Depression in Hiv Patients: A Double-Blind, Placebo-Controlled, Randomized Trial, International Clinical Psychopharmacology (2016)
5. Efficacy and Safety of Celecoxib for Treatment of Mild to Moderate Postpartum Depression: A Randomized, Double-Blind, Placebo-Controlled Trial, Archives of Gynecology and Obstetrics (2024)
6. Celecoxib Adjunctive Therapy for Acute Bipolar Mania: A Randomized, Double-Blind, Placebo-Controlled Trial, Bipolar Disorders (2015)
7. Celecoxib in Treatment of Postpartum Depression: A Case Report, Archives of Iranian Medicine (2023)
8. Riluzole Combination Therapy for Moderate-To-Severe Major Depressive Disorder: A Randomized, Double-Blind, Placebo-Controlled Trial, Journal of Psychiatric Research (2016)
Experts (# of related papers)
View all Related Experts
Shahin Akhondzadeh Basti (37)
Somaye Arabzadeh (5)
Other Related Docs
9. Duloxetine Add-On to Risperidone for Treatment of Negative Symptoms in Patients With Stable Schizophrenia: Randomized Double-Blind Placebo-Controlled Study, Pharmacopsychiatry (2016)
10. Effect of Adjunctive Celecoxib on Bdnf in Manic Patients Undergoing Electroconvulsive Therapy: A Randomized Double Blind Controlled Trial, Pharmacopsychiatry (2015)
11. Comparison of Saffron Versus Fluoxetine in Treatment of Mild to Moderate Postpartum Depression: A Double-Blind, Randomized Clinical Trial, Pharmacopsychiatry (2017)
12. Efficacy and Safety of Pentoxifylline Combination Therapy in Major Depressive Disorder: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial, International Clinical Psychopharmacology (2021)
13. Depression and Inflammation: Is There Any Role for Biomarkers?, Avicenna Journal of Medical Biotechnology (2019)
14. Citicoline Combination Therapy for Major Depressive Disorder: A Randomized, Double-Blind, Placebo-Controlled Trial, Clinical Neuropharmacology (2017)
15. Monoclonal Antibody a Promising Treatment for Depression, Avicenna Journal of Medical Biotechnology (2019)
16. The Effects of Pioglitazone Adjuvant Therapy on Negative Symptoms of Patients With Chronic Schizophrenia: A Double-Blind and Placebo-Controlled Trial, Human Psychopharmacology (2016)
17. Pioglitazone Adjunctive Therapy for Depressive Episode of Bipolar Disorder: A Randomized, Double-Blind, Placebo-Controlled Trial, Depression and Anxiety (2015)
18. Review of Clinical Studies Targeting Inflammatory Pathways for Individuals With Autism, Frontiers in Psychiatry (2019)
19. Simvastatin As an Adjuvant Therapy to Fluoxetine in Patients With Moderate to Severe Major Depression: A Double-Blind Placebo-Controlled Trial, Journal of Psychopharmacology (2015)
20. Efficacy and Safety of Celecoxib Monotherapy for Treatment of Moderate Depressive Symptoms Following Covid-19 Infection: A Randomized, Double-Blind, Placebo-Controlled Trial, Journal of Psychosomatic Research (2023)
21. Effect of Memantine Combination Therapy on Symptoms in Patients With Moderate-To-Severe Depressive Disorder: Randomized, Double-Blind, Placebo-Controlled Study, Journal of Clinical Pharmacy and Therapeutics (2017)
22. Does Oral Administration of Ketamine Accelerate Response to Treatment in Major Depressive Disorder? Results of a Double-Blind Controlled Trial, Journal of Affective Disorders (2018)
23. Acetaminophen As Adjuvant to Risperidone in Chronic Schizophrenia: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial, Iranian Journal of Psychiatry (2018)
24. Palmitoylethanolamide As Adjunctive Therapy in Major Depressive Disorder: A Double-Blind, Randomized and Placebo-Controlled Trial, Journal of Affective Disorders (2018)
25. The Trace of Evidence Based Medicine in Avicenna's Approaches, Journal of Medicinal Plants (2016)
26. Celecoxib As an Adjuvant to Fluvoxamine in Moderate to Severe Obsessive-Compulsive Disorder: A Double-Blind, Placebo-Controlled, Randomized Trial, Pharmacopsychiatry (2015)
27. Cinnamomum Tamala As an Adjuvant Therapy in the Treatment of Major Depressive Disorder: A Double-Blind, Randomized, Placebo-Controlled Clinical Trial With Placebo Control, Advances in Integrative Medicine (2020)
28. Targeting Inflammation by Flavonoids: Novel Therapeutic Strategy for Metabolic Disorders, International Journal of Molecular Sciences (2019)
29. Evidence for Anti-Inflammatory Effects of Adalimumab in Treatment of Patients With Major Depressive Disorder: A Pilot, Randomized, Controlled Trial, Clinical Neuropharmacology (2022)
30. Simvastatin Adjunct Therapy for Negative Symptoms of Schizophrenia: A Randomized Double-Blind Placebo-Controlled Trial, International Clinical Psychopharmacology (2017)
31. Simvastatin Versus Atorvastatin for Improving Mild to Moderate Depression in Post-Coronary Artery Bypass Graft Patients: A Double-Blind, Placebo-Controlled, Randomized Trial, Journal of Affective Disorders (2015)
32. Possible Involvement of Nitric Oxide in Antidepressant-Like Effect of Silymarin in Male Mice, Pharmaceutical Biology (2015)
33. Naproxen Adjunct to Fluoxetine for Moderate-To-Severe Obsessive-Compulsive Disorder: A Randomized, Double-Blind, Placebo-Controlled Trial, Psychiatry and Clinical Neurosciences (2024)
34. L-Carnosine As an Add-On to Risperidone for Treatment of Negative Symptoms in Patients With Stable Schizophrenia: A Double-Blind, Randomized Placebo-Controlled Trial, Psychiatry Research (2018)
35. Monoclonal Antibody for Reducing Memory and Learning Problems in Schizophrenia, Avicenna Journal of Medical Biotechnology (2018)
36. Introduction to Psychoneuroimmunology, Integrated Science (2024)
37. Risperidone Combination Therapy With Propentofylline for Treatment of Irritability in Autism Spectrum Disorders: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial, Clinical Neuropharmacology (2019)
38. Minocycline As Adjunctive Treatment to Risperidone in Children With Autistic Disorder: A Randomized, Double-Blind Placebo-Controlled Trial, Journal of Child and Adolescent Psychopharmacology (2016)
39. A Glance at the Therapeutic Potential of Irisin Against Diseases Involving Inflammation, Oxidative Stress, and Apoptosis: An Introductory Review, Pharmacological Research (2018)
40. Evidence Based Medicine and Herbal Medicine, Journal of Medicinal Plants (2016)
41. L-Carnosine Combination Therapy for Major Depressive Disorder: A Randomized, Double-Blind, Placebo-Controlled Trial, Journal of Affective Disorders (2020)
42. Palmitoylethanolamide As Adjunctive Therapy for Autism: Efficacy and Safety Results From a Randomized Controlled Trial, Journal of Psychiatric Research (2018)